IDH2 and cancer: Thus, Sulkowski et al. showed that IDH1/IDH2 mutations induce a HR defect that renders cancer cells exquisitely sensitive to poly (adenosine 5′-diphosphate-ribose) polymerase (PARP) inhibitors [176].